



**Chris Twelves**

**Kontakt**

Chris Twelves

## Publikationen (3)

Blagden S, Spicer J, Twelves C, Jones K, Prince J, Inatani M, Shiokawa R, Noguchi K, Pope L, Riisnaes R, Swales K, Decordova S, Anthoney A, Pinato D, Zivi A, Stavrika C, Josephs D, Omlin A, Banerji U. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. *Clin Cancer Res* 2014; 20:5908-17.

Jörger M, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Schellens J, Jodrell D, Izquierdo M, Sleeboom H, Huitema A, Richel D, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J, Stocchi E, Martoni A, Sorio R, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. *Clinical pharmacokinetics* 2007; 46:1051-68.

Ravaud A, Cerny T, Terret C, Wanders J, Bui B, Hess D, Droz J, Fumoleau P, Twelves C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an EORTC study. *European journal of cancer (Oxford, England : 1990)* 2005; 41:702-7.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)